Inhibikase Therapeutics (IKT) Corporate presentation summary

Disease overview and unmet need

• Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease with a ~30% five-year mortality rate, reduced quality of life, and high economic burden.

• The PAH market is valued at $7.6 billion, with most treatments focused on vasodilation rather than addressing the underlying disease mechanism.

• Current therapies include 15 approved vasodilators and only one approved anti-proliferative agent, highlighting a significant unmet need.

Scientific rationale and mechanism

• PAH is driven by uncontrolled proliferation of vascular cells, leading to vascular remodeling and right heart failure.

• Imatinib, a tyrosine kinase inhibitor (TKI), targets PDGFR and c-kit, blocking cell signaling that drives vascular remodeling.

• Preclinical studies show imatinib reverses vascular remodeling, reduces right ventricular pressure, and improves survival in animal models.

Product profile and innovation

• IKT-001 is a novel oral pro-drug of imatinib, engineered for improved gastrointestinal (GI) tolerability and optimal efficacy in PAH.

• IKT-001 demonstrates >2.5x improvement in GI tolerability in preclinical studies compared to imatinib.

• Bioequivalence to imatinib has been established in healthy volunteers, supporting clinical development.